PRTN3 and rheumatoid arthritis: The proportion of patients with SDAI and CDAI LDA and/or remission in patients with RF/ACPA double-positive RA and RF/ACPA double-negative RA was higher with abatacept as an earlier- versus later-line biologic at 2 years (Fig. 4A).